Denali's Brain-Crossing Drug Reaches Market as Alzheimer Pipeline Advances

Denali Therapeutics has crossed a milestone that matters well beyond rare disease: it has proven that its Enzyme TransportVehicle platform can win FDA approval, reach the brain, and generate real-world commercial uptake. AVLAYAH, approved in March 2026 for the neurological effects of Hunter syndrome (MPS II), brought in $3.6 million in its first full quarter on the US market — a modest number against the company's $127.6 million quarterly loss, but one that validates the platform itself.

The blood-brain barrier has long been the central obstacle in neurodegenerative disease drug development. Most large molecules cannot cross it efficiently, limiting treatment of Alzheimer's, Parkinson's, and related disorders. Denali's ETV technology attaches therapeutic payloads to a transferrin-receptor-binding scaffold that actively ferries them across. AVLAYAH is the proof-of-concept; Alzheimer's is the prize.

This quarter, Denali advanced two ETV-enabled Alzheimer's candidates into clinical development: DNL628, an antisense oligonucleotide targeting MAPT — the gene encoding tau protein — and DNL921, an amyloid-targeting antibody. Both could yield initial data in 2027. If either shows brain target engagement at meaningful levels, it would represent a genuine step forward in the decades-long effort to treat the most common cause of age-related cognitive decline.

Not every bet paid off. DNL151, an LRRK2 inhibitor co-developed with Biogen for idiopathic Parkinson's disease, missed its Phase 2b endpoints in the LUMA study. Denali is pressing on in a genetically defined LRRK2-variant subset, an important reminder that pathway validation and delivery do not guarantee efficacy. A progranulin therapy for frontotemporal dementia lost its Takeda partner but continues generating biomarker data.

For longevity-focused readers, the broader implication is technological: a scalable blood-brain barrier delivery platform, now with regulatory and commercial proof points, could eventually lower the barrier — literally — to treating the neurodegenerative diseases that most threaten late-life cognitive function.